Filing Details

Accession Number:
0001209191-21-048652
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-07-29 18:32:21
Reporting Period:
2021-07-27
Accepted Time:
2021-07-29 18:32:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
860730 Hca Healthcare Inc. HCA Services-General Medical & Surgical Hospitals, Nec (8062) 273865930
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1632834 D. Jane Englebright One Park Plaza
Nashville TN 37203
Svp And Chief Nursing Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-07-27 3,300 $47.97 6,809 No 4 M Direct
Common Stock Acquisiton 2021-07-27 5,500 $68.96 12,309 No 4 M Direct
Common Stock Disposition 2021-07-27 4,782 $247.69 7,527 No 4 F Direct
Common Stock Disposition 2021-07-29 200 $249.36 7,327 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 F Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Appreciation Right Disposition 2021-07-27 1,375 $0.00 1,375 $47.97
Common Stock Stock Appreciation Right Disposition 2021-07-27 1,925 $0.00 1,925 $47.97
Common Stock Stock Appreciation Right Disposition 2021-07-27 5,500 $0.00 5,500 $68.96
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2024-02-05 No 4 M Direct
0 2024-02-05 No 4 M Direct
0 2025-02-04 No 4 M Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $249.30 to $249.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. The stock appreciation rights vested in four equal annual installments beginning on February 5, 2015.
  3. The stock appreciation rights vested at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the achievement of certain annual EBITDA performance targets.
  4. The stock appreciation rights vested in four equal annual installments beginning on February 4, 2016.